Home>Topics>>Piper Jafrfray says Vertex's ([[VRTX]] -0.6%) Incivek sales are likely to decline further after the FDA forced the drug developer to place a warning regarding fatal and non-fatal serious skin ...
Piper Jafrfray says Vertex's ([[VRTX]] -0.6%) Incivek sales are likely to decline further after the FDA forced the drug developer to place a warning regarding fatal and non-fatal serious skin ...
Piper Jafrfray says Vertex's (
VRTX -0.6% ) Incivek sales are likely to decline further after the FDA forced the drug developer to place a warning regarding fatal and non-fatal serious skin reactions on the boxes containing its HCV treatment. The firm maintains a Neutral rating on the stock. Post ...
Read the rest of this article on SeekingAlpha.com: SA Currents